CARVYKTI 3.2 × 10 6 – 1 × 108 cells dispersion for infusion | medicines.ie

Company: Janssen Sciences Ireland (a Johnson & Johnson Company)
Active Ingredient: ciltacabtagene autoleucel
Dosage Form: Dispersion for infusion
Legal Category: A - prescription, may not be renewed

Direct Healthcare Professional Communications

DHPC - CD19 or BCMA directed CAR T-cell therapies – Risk of secondary malignancy of T-cell origin

Direct Healthcare Professional Communication (DHPC)

PDF627.68 KB

Janssen Sciences Ireland (a Johnson & Johnson Company)

Janssen Sciences Ireland UC, Barnahely, Ringaskiddy, IRL - Co. Cork P43 FA46, P43 FA46 Ringaskiddy

Website: https://innovativemedicine.jnj.com/ireland/
Telephone: +3531800709122
Email: medinfo@its.jnj.com